Notice of Retraction and Replacement: Kessler RC, et al. Associations of Housing Mobility Interventions for Children in High-Poverty Neighborhoods With Subsequent Mental Disorders During Adolescence. JAMA. 2014;311(9):937-947.

Letters COMMENT u0026 RESPONSE Notice of Retraction and Replacement: Kessler RC, et al. Associations of Housing Mobility Interventions for Children in High-Poverty Neighborhoods With Subsequent Mental Disorders During Adolescence. JAMA. 2014;311(9):937-947. To the Editor In the Original Investigation entitled “Associa- tions of Housing Mobility Interventions for Children in High- Poverty Neighborhoods With Subsequent Mental Disorders During Adolescence” published in the March 5, 2014, issue of JAMA, 1 we inadvertently reported incorrect confidence inter- vals and a P value in 2 tables. This study explored the associa- tions between 2 types of vouchers given to volunteer public housing families to encourage them to move out of high- poverty neighborhoods (when children were age 0-8 years) and no intervention and subsequent mental disorders in 2872 ado- lescents (at age 13-19 years). The errors were due to failure to update results from an earlier set of models. These errors were discovered in the course of rechecking the code in conjunction with a secondary analy- sis. We have corrected these errors and confirmed that there are no other errors after reviewing our original analysis and findings. The corrections for these errors have changed 1 of the major findings of the study: the previously reported statisti- cally significant reduction in major depressive disorder in girls was not statistically significant. Thus, we have requested that the original article be retracted and replaced. In Table 4, incorrect 95% CIs were reported for major de- pressive disorder for each of the groups; the absolute risks (ARs) and absolute risk reductions (ARRs) have not changed. For the AR in the low-poverty voucher group (n = 1424), the correct data are AR 6.8%, 95% CI 4.9%-8.7% (not 6.8%, 95% CI −12.0% to 25.6%); and the correct data for the ARR are 0.3%, 95% CI −1.8% to 2.3% (not 0.3%, 95% CI, −27.0% to 27.6%). For the AR in the traditional voucher group (n = 1074), the correct data are AR 6.1%, 95% CI 4.5% to 7.7% (not 6.1%, 95% CI −20.1% to 32.4%) and for the ARR, the correct data are 1.0%, 95% CI −1.0% to 3.0% (not 1.0%, 95% CI −30.7% to 32.7%). For the AR in the control group (n = 1173), the correct data are AR 7.1%, 95% CI 5.8% to 8.4% (not 7.1%, 95% CI −21.8% to 35.9%). An incor- rect CI was also reported in Table 5 for the AR of conduct dis- order among girls in the traditional voucher group (n = 533). The correct data are AR 0.3%, 95% CI −0.1% to 0.7% (not 0.3%, 95% CI 0.0% to 0.7%). An incorrect P value was also reported in Table 5 for the effect of the traditional voucher interven- tion on major depressive disorder among girls. The correct P value is .06 (not .04). None of the other findings in Tables 4 or 5 were affected by the errors. The corrections for these errors indicate that the previ- ously reported statistically significant reduction in major de- pressive disorder in girls was not statistically significant, and this result has been removed from the conclusion of the ar- ticle. The article now concludes: “Interventions to encourage moving out of high-poverty neighborhoods were associated with increased rates of depression, PTSD, and conduct disor- der among boys and a reduced rate of conduct disorder among girls. Better understanding of interactions among individual, family, and neighborhood risk factors is needed to guide fu- ture public housing policy changes.” We regret these errors as well as the confusion caused to JAMA, readers, and potentially to public housing policy plan- ners. The abstract, text, and Tables 4 and 5 of the original ar- ticle have been corrected and replaced online. 1 An additional online supplement has been added that includes a version of the original article with the errors highlighted and a version of the replacement article with the corrections highlighted. Ronald C. Kessler, PhD Greg J. Duncan, PhD Lisa A. Gennetian, PhD Lawrence F. Katz, PhD Jeffrey R. Kling, PhD Nancy A. Sampson, BA Lisa Sanbonmatsu, PhD Alan M. Zaslavsky, PhD Jens Ludwig, PhD Author Affiliations: Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts (Kessler, Sampson, Zaslavsky); School of Education, University of California-Irvine (Duncan); National Bureau of Economic Research, Cambridge, Massachusetts (Gennetian, Katz, Kling, Sanbonmatsu, Ludwig); Department of Economics, Harvard University, Cambridge, Massachusetts (Katz); Congressional Budget Office, Washington, DC (Kling); Harris School of Public Policy, University of Chicago, Chicago, Illinois (Ludwig). Corresponding Author: Ronald C. Kessler, PhD, Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115 (kessler @hcp.med.harvard.edu). Published Online: June 17, 2016. doi:10.1001/jama.2016.6187 Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Kessler reported that he has been a consultant for AstraZeneca, Analysis Group, Bristol-Myers Squibb, Cerner-Galt Associates, Eli Lilly, GlaxoSmithKline, HealthCore, Health Dialog, Hoffman-LaRoche, Integrated Benefits Institute, J u0026 J Wellness u0026 Prevention, John Snow, Kaiser Permanente, Lake Nona Institute, Matria, Mensante, Merck, Ortho-McNeil Janssen Scientific Affairs, Pfizer, Primary Care Network, Research Triangle Institute, sanofi-aventis, Shire US, SRA International, Takeda Global Research u0026 Development, Transcept Pharmaceuticals, and Wyeth-Ayerst; has served on advisory boards for Appliance Computing II, Eli Lilly, Mindsite, Ortho-McNeil Janssen Scientific Affairs, Johnson u0026 Johnson, Plus One Health Management, and Wyeth-Ayerst; has had research support for his epidemiological studies from Analysis Group Inc, Bristol-Myers Squibb, Eli Lilly u0026 Company, EPI-Q, GlaxoSmithKline, Johnson u0026 Johnson Pharmaceuticals, Ortho-McNeil Janssen Scientific Affairs, Pfizer, sanofi-aventis, Shire US, and Walgreens; and owns 25% share in DataStat. Dr Gennetian reported that he has served on advisory boards for Family Self Sufficiency TWG, Administration for Children and Families, and National Opinion Research Center, University of Chicago. Dr Katz reported that he has served on advisory boards for Manpower Demonstration Research Corporation and the Russell Sage Foundation. Dr Ludwig reported that he serves on advisory jama.com (Reprinted) JAMA July 12, 2016 Volume 316, Number 2 Copyright 2016 American Medical Association. All rights reserved. Downloaded From: http://jamanetwork.com/ by a University of California - Irvine User on 12/30/2016